Literature DB >> 606763

Correlation of laboratory studies with clinical responses to A/New Jersey influenza vaccines.

F A Ennis, R E Mayner, D W Barry, J E Manischewitz, R C Dunlap, M W Verbonitz, R M Bozeman, G C Schild.   

Abstract

The large, uniformly performed clinical investigations with influenza A/New Jersey vaccines provided an opportunity to correlate results of laboratory tests of vaccine with human reactivity and antibody responses. These vaccines were given to large numbers of subjects under code, and significant differences in immunogenicity and reactivity were observed in unprimed individuals. A single, relatively large dose of intact virus was more immunogenic and reactive than split-virus vaccines in unprimed subjects. Differences in immunogenicity and reactivity in unprimed subjects correlated with the amount of intact virus in the vaccines (measured by column chromatography or electron microscopy) and with the amount of viral hemagglutinin in the vaccine (measured by immunodiffusion), but not with the number of chick cell-agglutinating units.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 606763     DOI: 10.1093/infdis/136.supplement_3.s397

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  12 in total

1.  Relative antigenicity in mice of H1N1, H3N2 and B strains present in inactivated influenza virus vaccines.

Authors:  M L Profeta; M Ruggeri
Journal:  Eur J Epidemiol       Date:  1987-03       Impact factor: 8.082

2.  Safety and immunogenicity of 2009 pandemic H1N1 influenza vaccination in perinatally HIV-1-infected children, adolescents, and young adults.

Authors:  Patricia M Flynn; Sharon Nachman; Petronella Muresan; Terence Fenton; Stephen A Spector; Coleen K Cunningham; Robert Pass; Ram Yogev; Sandra Burchett; Barbara Heckman; Anthony Bloom; L Jill Utech; Patricia Anthony; Elizabeth Petzold; Wende Levy; George K Siberry; Ruth Ebiasah; Judi Miller; Edward Handelsman; Adriana Weinberg
Journal:  J Infect Dis       Date:  2012-05-21       Impact factor: 5.226

3.  High dose trivalent influenza vaccine compared to standard dose vaccine in patients with rheumatoid arthritis receiving TNF-alpha inhibitor therapy and healthy controls: Results of the DMID 10-0076 randomized clinical trial.

Authors:  Jack T Stapleton; Nancy Wagner; Rebecca Tuetken; Abbie R Bellamy; Heather Hill; Sonnie Kim; Patricia L Winokur
Journal:  Vaccine       Date:  2020-04-12       Impact factor: 3.641

4.  Safety and immunogenicity of inactivated, Vero cell culture-derived whole virus influenza A/H5N1 vaccine given alone or with aluminum hydroxide adjuvant in healthy adults.

Authors:  Wendy A Keitel; Cornelia L Dekker; ChrisAnna Mink; James D Campbell; Kathryn M Edwards; Shital M Patel; Dora Y Ho; Helen K Talbot; Kuo Guo; Diana L Noah; Heather Hill
Journal:  Vaccine       Date:  2009-03-25       Impact factor: 3.641

Review 5.  Challenges of Making Effective Influenza Vaccines.

Authors:  Sigrid Gouma; Elizabeth M Anderson; Scott E Hensley
Journal:  Annu Rev Virol       Date:  2020-05-11       Impact factor: 10.431

Review 6.  Vaccination against virus diseases.

Authors:  K R Schell
Journal:  Soz Praventivmed       Date:  1979-10

7.  Comparative antigenicity and immunogenicity of A/USSR/77 influenza vaccines in normal and primed mice.

Authors:  C McLaren; G E Grubbs; E Staton; W Barthlow; G Quinnan; F A Ennis
Journal:  Infect Immun       Date:  1980-04       Impact factor: 3.441

8.  In vitro evidence that commercial influenza vaccines are not similar in their ability to activate human T cell responses.

Authors:  Mary Dawn T Co; Laura Orphin; John Cruz; Pamela Pazoles; Karin M Green; James Potts; Anita M Leporati; Jenny Aurielle B Babon; James E Evans; Francis A Ennis; Masanori Terajima
Journal:  Vaccine       Date:  2008-10-31       Impact factor: 3.641

9.  Vaccines and antiviral drugs in pandemic preparedness.

Authors:  Arnold S Monto
Journal:  Emerg Infect Dis       Date:  2006-01       Impact factor: 6.883

10.  Influenza Vaccine Manufacturing: Effect of Inactivation, Splitting and Site of Manufacturing. Comparison of Influenza Vaccine Production Processes.

Authors:  Theone C Kon; Adrian Onu; Laurentiu Berbecila; Emilia Lupulescu; Alina Ghiorgisor; Gideon F Kersten; Yi-Qing Cui; Jean-Pierre Amorij; Leo Van der Pol
Journal:  PLoS One       Date:  2016-03-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.